CODX

Co-Diagnostics Inc

Co-Diagnostics shares surged nearly 80% on Tuesday after the company expanded development efforts for a PCR test targeting the Bundibugyo strain of the Ebola virus.

Wall Street’s speculative engine is running hot as investors pile into AI infrastructure, autonomous driving, biotech innovation, and advanced manufacturing plays driving some of the market’s biggest momentum stories. $HTT, $NTHI, $HLIT, $CODX, $RDW, $PONY, $MOD, $BAC, $STT, $BCS

Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara PR Newswire SALT LAKE CITY, May 26, 2026 Joint development strategy has been developed to address international deployment...

As capital continues flowing into high-growth sectors tied to artificial intelligence, biotechnology, diagnostics, and defense technology, several emerging companies are rapidly capturing investor attention through financings, acquisitions, regulatory approvals, and platform expansion strategies. $SBFM, $TGNT, $CODX, $JUNS, $VIDA, $QUCY, $GFS, $GOOG, $MSFT, $NVDA

Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire SALT LAKE CITY, May 19, 2026 SALT LAKE CITY, May 19, 2026 /PRNewswire/ --Co-Diagnostics, Inc...

Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX

Global public health systems have become increasingly focused on rapid diagnostic readiness since the COVID-19 pandemic exposed the risks of delayed outbreak detection and centralized testing bottlenecks. As emerging infectious disease threats continue to trigger international emergency responses, companies with the ability to quickly develop and deploy molecular diagnostic assays are drawing renewed investor attention.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) are surging Tuesday after the molecular diagnostics company announced it has completed the assay development strategy for the ...

Global public health systems have become increasingly focused on rapid diagnostic readiness since the COVID-19 pandemic exposed the risks of delayed outbreak detection and centralized testing bottlenecks. As emerging infectious disease threats continue to trigger international emergency responses, companies with the ability to quickly develop and deploy molecular diagnostic assays are drawing renewed investor attention.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) are surging Tuesday after the molecular diagnostics company announced it has completed the assay development strategy for the ...

The molecular diagnostics company announced it has completed the assay development strategy for the Bundibugyo strain of the Ebola virus.